P634: EARLY-STAGE MEASURABLE RESIDUAL DISEASE DYNAMICS AND IGHV REPERTOIRE RECONSTITUTION DURING VENETOCLAX AND OBINUTUZUMAB TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA

• Paul Hengeveld,
• Joyce Schilperoord-Vermeulen,
• Michèle van der Klift,
• Julie Dubois,
• Pieter Martijn Kolijn,
• François Kavelaars,
• Melissa Rijken,
• Johan Dobber,
• Kazem Nasserinejad,
• Sabina Kersting,
• Peter Westerweel,
• Arnon Kater,
• Anton Langerak,
• Mark-David Levin

Affiliations

Paul Hengeveld

1 Erasmus MC, Immunology, Rotterdam, The Netherlands

Joyce Schilperoord-Vermeulen

1 Erasmus MC, Immunology, Rotterdam, The Netherlands

Michèle van der Klift

1 Erasmus MC, Immunology, Rotterdam, The Netherlands

Julie Dubois

3 Amsterdam UMC, locatie AMC, Hematology, Amsterdam, The Netherlands

Pieter Martijn Kolijn

1 Erasmus MC, Immunology, Rotterdam, The Netherlands

François Kavelaars

4 Erasmus MC, Hematology, Rotterdam, The Netherlands

Melissa Rijken

4 Erasmus MC, Hematology, Rotterdam, The Netherlands

Johan Dobber

3 Amsterdam UMC, locatie AMC, Hematology, Amsterdam, The Netherlands

Kazem Nasserinejad

5 Erasmus MC, HOVON data center, Rotterdam, The Netherlands

Sabina Kersting

6 Haga Hospital (Leyweg), Hematology, Den Haag, The Netherlands

Peter Westerweel

2 Albert Schweitzer Hospital, Internal Medicine, Dordrecht, The Netherlands

Arnon Kater

3 Amsterdam UMC, locatie AMC, Hematology, Amsterdam, The Netherlands

Anton Langerak

1 Erasmus MC, Immunology, Rotterdam, The Netherlands

Mark-David Levin

2 Albert Schweitzer Hospital, Internal Medicine, Dordrecht, The Netherlands